We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Inflammation Marker Linked to Increased Cancer Death Risk

By LabMedica International staff writers
Posted on 28 Nov 2012
The measurement of blood levels of high-sensitive C-reactive protein in apparently cancer-free men could potentially help identify those at increased risk for death from cancer.

High-sensitive C-reactive protein (hs-CRP) is an important marker of inflammation has been linked to the initiation and progression of several types of cancer, as well as to the progression of atherosclerosis and cardiovascular disease. More...


Scientists at the Seoul National University Hospital (South Korea) retrospectively analyzed data from 33,556 individuals who had completed medical checkups and had been screened for blood hs-CRP at a health-screening center between May 1995 and December 2006. The average follow-up was 9.4 years, and during that time, 1,054 deaths from all causes and 506 deaths from cancer were recorded.

The hs-CRP levels were measured with a highly sensitive latex-enhanced immunoassay run on an automated chemistry analyzer (Hitachi; Tokyo, Japan). The investigators adjusted for several variables, including age, diabetes, smoking status and exercise habits and found that men with the highest level of hs-CRP in their blood, 3 mg /L or more, were 38% more likely to have died from any cause compared with men with the lowest hs-CRP level of 1 mg/L or less. They were also 61% more likely to have died from cancer. For women, after adjusting for a number of variables, no statistically significant association was observed for hs-CRP level and death from any cause or death from cancer.

Through analysis of associations between hs-CRP levels and site-specific cancers, the scientists found that a significant relationship existed only for lung cancer. After adjusting for multiple variables, individuals with the highest hs-CRP level were more than twice as likely to die from lung cancer compared with those with the lowest hs-CRP level. The association between hs-CRP levels and all-cause mortality and cancer mortality was stronger in lean individuals compared with those who were overweight.

Minseon Park, MD, PhD, MPH, the senior author of the study said, "We wanted to determine whether there was a relationship between a well-established marker of inflammation, high-sensitive C-reactive protein, and death from all causes, death from cancer or death from a site-specific cancer in Koreans." The study was published in the November 2012 edition of the journal Cancer Epidemiology, Biomarkers & Prevention.

Related Links:

Seoul National University Hospital
Hitachi



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.